EAGLE PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2021-10-14 08:04:08 ET EGRX

Item 7.01 Regulation FD Disclosure.

On October 14, 2021, Eagle Pharmaceuticals, Inc., or the Company, released an updated investor presentation of the Company's business model, products and product candidates. The investor presentation will be used from time to time in meetings with investors.

A copy of the above-referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

An excerpt of the presentation slides from the investor presentation are attached hereto as Exhibit 99.2 to this Current Report.

Item 9.01 Financial Statements and Exhibits.